Stem Cells from Placenta Show Promise for Treating Heart Failure
stem cells collected from placenta, which is generally discarded after childbirth, show promise as a treatment for heart failure. Found in STEM CELLS Translational Medicine, a new study using mice determined that human-derived adherent cells (PDAC® cells) significantly improved cardiac function when injected into the heart muscle.
Cell therapies for cardiac repair have generated considerable interest in recent years. While earlier studies using autologous bone marrow transplantation (that is, stem cells collected from the patient’s own bone marrow) helped improve cardiac function after myocardial infarction (MI); more recent studies showed no benefit in the early stages after MI. This has led researchers to question whether mesenchymal stem cells from sources other than bone marrow, such as cord blood and placenta tissue, might yield better results.
Among those interested in this is an international team co-led by Patrick C.H. Hsieh of Taiwan’s Institute of Biomedical Sciences, Academia Sinica, Taipei, and Uri Herzberg of Celgene Cellular Therapeutics, Warren, New Jersey, U.S. They recently undertook a study to test the therapeutic effects of PDA-001, an intravenous formulation of PDAC® cells, in mice. The researchers were also testing the best way to deliver the therapy.
“Three weeks after chronic heart failure was induced in the animals they were treated with the stem cells by either direct intramyocardial (IM) or intravenous (IV) injection,” Dr. Hsieh said. “The results showed that the IM injections significantly improved the left ventricle systolic and diastolic functions compared with injection of vehicle or IV injection of PDA-001.
“The IM injections also decreased cardiac fibrosis in the vicinity of the injection sites. We repeatedly observed improvement of cardiac function in the injected sites following IM PDA-001 treatment,” Dr. Herzberg added. “Based on these results, we want to continue our investigations to optimize the effect through controlling the dose, timing and delivery.”
“In this animal model of progressive heart injury, stem cells isolated from placenta showed promise as an off-the-shelf therapy for cardiac repair, warranting the need for testing in additional models,” said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.
Original publication
“Human Placenta-derived Adherent Cells Improve Cardiac Performance in Mice with Chronic Heart Failure.”; STEM CELLS Translational Medicine
Most read news
Original publication
“Human Placenta-derived Adherent Cells Improve Cardiac Performance in Mice with Chronic Heart Failure.”; STEM CELLS Translational Medicine
Organizations

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Deuterium Depletion: A New Concept in Anticancer Drug Development

So-called junk DNA plays critical role in mammalian development - Knocking out transposon promoter leads to pup death in mice; similar promoters found in many mammals
Leprosy strain genotyped from medieval pilgrim at UK burial site - Medieval leprosy victim in UK cemetery was likely a religious pilgrim, possibly from overseas
Biological wires carry electricity thanks to special amino acids

Bioactive novel compounds from endangered tropical plant species
MicroRNA network study implicates rewired interactions in cancer
VAXIMM receives grant to expand pipeline of oral cancer vaccines
Merck and Pfizer receive FDA approval for kidney cancer therapy - BAVENCIO® (avelumab) plus Axitinib Combination for Patients with Advanced Renal Cell Carcinoma

New brain-computer interface allows man with ALS to ‘speak’ again - Technology developed by UC Davis Health restores interpersonal communication
Genome analysis of marine microbe reveals a metabolic minimalist
Algeta appoints Dr. Gillies O'Bryan-Tear as Chief Medical Officer
